The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation
Open accessAbstract
Background: Resistance to an immune checkpoint inhibitor (ICI) is a major obstacle in cancer immunotherapy. The causes of ICI resistance include major histocompatibility complex (MHC)/histocompatibility locus antigen (HLA) class I loss, neoantigen loss, and incomplete antigen presentation. Elimination by natural killer (NK) cells would be expected to be an effective strategy for the treatment of these ICI-resistant tumors. We previously demonstrated that a lipid nanoparticle containing a stimulator of an interferon gene (STING) agonist (STING-LNP) efficiently induced antitumor activity via the activation of NK cells. Thus, we evaluated the potential of reducing ICI resistance by STING-LNPs. Methods: Lung metastasis of a B16-F10 mouse melanoma was used as an anti-programmed cell death 1 (anti-PD-1)-resistant mouse model. The mice were intravenously injected with the STING-LNP and the mechanism responsible for the improvement of anti-PD-1 resistance by the STING-LNPs was analyzed by RT-qPCR and flow cytometry. The dynamics of STING-LNP were also investigated. Results: Although anti-PD-1 monotherapy failed to induce an antitumor effect, the combination of the STING-LNP and anti-PD-1 exerted a synergistic antitumor effect. Our results indicate that the STING-LNP treatment significantly increased the expression of CD3, CD4, NK1.1, PD-1 and interferon (IFN)-γ in lung metastases. This change appears to be initiated by the type I IFN produced by liver macrophages that contain the internalized STING-LNPs, leading to the systemic activation of NK cells that express PD-1. The activated NK cells appeared to produce IFN-γ, resulting in an increase in the expression of the PD ligand 1 (PD-L1) in cancer cells, thus leading to a synergistic antitumor effect when anti-PD-1 is administered. Conclusions: We provide a demonstration to show that a STING-LNP treatment can overcome PD-1 resistance in a B16-F10 lung metastasis model. The mechanism responsible for this indicates that NK cells are activated by stimulating the STING pathway which, in turn, induced the expression of PD-L1 on cancer cells. Based on the findings reported herein, the STING-LNP represents a promising candidate for use in combination therapy with anti-PD-1-resistant tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing
Chen, Q., Sun, L., & Chen, Z. J. (2016) · Nature Immunology · doi:10.1038/ni.3558 · Cited by 2,333
Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Chen, L., & Han, X. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80011 · Cited by 1,437
Nanoparticle uptake: The phagocyte problem
Gustafson, H. H., Holt-Casper, D., Grainger, D. W., & Ghandehari, H. (2015) · Nano Today · doi:10.1016/j.nantod.2015.06.006 · Cited by 1,411
The Liver as an Immunological Organ
Racanelli, V., & Rehermann, B. (2006) · Hepatology · doi:10.1002/hep.21060 · Cited by 1,377
Nanoparticle–liver interactions: Cellular uptake and hepatobiliary elimination
Zhang, Y.-N., Poon, W., Tavares, A. J., McGilvray, I. D., & Chan, W. C. W. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.020 · Cited by 1,349
Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S.-R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101159 · Cited by 1,192
The Spleen in Local and Systemic Regulation of Immunity
Bronte, V., & Pittet, M. J. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.010 · Cited by 1,064
Crispe, I. N. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132629 · Cited by 986
Neoantigen-directed immune escape in lung cancer evolution
The TRACERx consortium, Rosenthal, R., Cadieux, E. L., Salgado, R., Bakir, M. A., Moore, D. A., Hiley, C. T., Lund, T., Tanić, M., Reading, J. L., et al. (2019) · Nature · doi:10.1038/s41586-019-1032-7 · Cited by 946
Kubes, P., & Jenne, C. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052415 · Cited by 923
A STING-activating nanovaccine for cancer immunotherapy
Luo, M., Wang, H., Wang, Z., Cai, H., Lu, Z., Li, Y., Du, M., Huang, G., Wang, C., Chen, X., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.52 · Cited by 900
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
De Henau, O., Rausch, M., Winkler, D., Campesato, L. F., Liu, C., Cymerman, D. H., Budhu, S., Ghosh, A., Pink, M., Tchaicha, J., et al. (2016) · Nature · doi:10.1038/nature20554 · Cited by 860
Juneja, V. R., McGuire, K. A., Manguso, R. T., LaFleur, M. W., Collins, N., Haining, W. N., Freeman, G. J., & Sharpe, A. H. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160801 · Cited by 851
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99317 · Cited by 817
Benson, D. M., Bakan, C. E., Mishra, A., Hofmeister, C. C., Efebera, Y., Becknell, B., Baiocchi, R. A., Zhang, J., Yu, J., Smith, M. K., et al. (2010) · Blood · doi:10.1182/blood-2010-02-271874 · Cited by 807
Blank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., & Gajewski, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3259 · Cited by 772
Arlauckas, S. P., Garris, C. S., Kohler, R. H., Kitaoka, M., Cuccarese, M. F., Yang, K. S., Miller, M. A., Carlson, J. C., Freeman, G. J., Anthony, R. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3604 · Cited by 669
Shae, D., Becker, K. W., Christov, P., Yun, D. S., Lytton-Jean, A. K. R., Sevimli, S., Ascano, M., Kelley, M., Johnson, D. B., Balko, J. M., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-018-0342-5 · Cited by 668
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
Kim, J. M., & Chen, D. S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw217 · Cited by 648
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
Kleffel, S., Posch, C., Barthel, S. R., Mueller, H., Schlapbach, C., Guenova, E., Elco, C. P., Lee, N., Juneja, V. R., Zhan, Q., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.052 · Cited by 639
Marcus, A., Mao, A. J., Lensink-Vasan, M., Wang, L., Vance, R. E., & Raulet, D. H. (2018) · Immunity · doi:10.1016/j.immuni.2018.09.016 · Cited by 611
The trafficking of natural killer cells
Grégoire, C., Chasson, L., Luci, C., Tomasello, E., Geissmann, F., Vivier, E., & Walzer, T. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00563.x · Cited by 569
Pesce, S., Greppi, M., Tabellini, G., Rampinelli, F., Parolini, S., Olive, D., Moretta, L., Moretta, A., & Marcenaro, E. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.04.025 · Cited by 465
STING Polymer Structure Reveals Mechanisms for Activation, Hyperactivation, and Inhibition
Ergun, S. L., Fernandez, D., Weiss, T. M., & Li, L. (2019) · Cell · doi:10.1016/j.cell.2019.05.036 · Cited by 401
Nanoparticulate STING agonists are potent lymph node–targeted vaccine adjuvants
Hanson, M. C., Crespo, M. P., Abraham, W., Moynihan, K. D., Szeto, G. L., Chen, S. H., Melo, M. B., Mueller, S., & Irvine, D. J. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79915 · Cited by 381
SLC19A1 transports immunoreactive cyclic dinucleotides.
Luteijn, R. D., Zaver, S. A., Gowen, B. G., Wyman, S. K., Garelis, N. E., Onia, L., McWhirter, S. M., Katibah, G. E., Corn, J. E., Woodward, J. J., et al. (2019) · Nature · doi:10.1038/s41586-019-1553-0 · Cited by 379
Liu, Y., Cheng, Y., Xu, Y., Wang, Z., Du, X., Li, C., Peng, J., Gao, L., Liang, X., & Ma, C. (2017) · Oncogene · doi:10.1038/onc.2017.209 · Cited by 366
Liver Macrophages: Old Dogmas and New Insights
Guillot, A., & Tacke, F. (2019) · Hepatology Communications · doi:10.1002/hep4.1356 · Cited by 335
Sato, Y., Hatakeyama, H., Sakurai, Y., Hyodo, M., Akita, H., & Harashima, H. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.09.009 · Cited by 309
Self-citationNK cells mediate clearance of CD8 + T cell–resistant tumors in response to STING agonists
Nicolai, C. J., Wolf, N., Chang, I.-C., Kirn, G., Marcus, A., Ndubaku, C. O., McWhirter, S. M., & Raulet, D. H. (2020) · Science Immunology · doi:10.1126/sciimmunol.aaz2738 · Cited by 268
Cheng, N., Watkins-Schulz, R., Junkins, R. D., David, C. N., Johnson, B. M., Montgomery, S. A., Peine, K. J., Darr, D. B., Yuan, H., McKinnon, K. P., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120638 · Cited by 260
Liu, Y., Crowe, W. N., Wang, L., Lu, Y., Petty, W. J., Habib, A. A., & Zhao, D. (2019) · Nature Communications · doi:10.1038/s41467-019-13094-5 · Cited by 254
Perche, F., Benvegnu, T., Berchel, M., Lebegue, L., Pichon, C., Jaffrès, P.-A., & Midoux, P. (2011) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2010.12.010 · Cited by 218
Nakamura, T., Miyabe, H., Hyodo, M., Sato, Y., Hayakawa, Y., & Harashima, H. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.026 · Cited by 198
Self-citationCharacterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells.
Seliger, B., Wollscheid, U., Momburg, F., Blankenstein, T. J. F., & Huber, C. (2001) · PubMed · Cited by 195
A new adjuvant delivery system ‘cyclic di-GMP/YSK05 liposome’ for cancer immunotherapy
Miyabe, H., Hyodo, M., Nakamura, T., Sato, Y., Hayakawa, Y., & Harashima, H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.004 · Cited by 163
Self-citationPD-L1 blockade enhances anti-tumor efficacy of NK cells
Oyer, J. L., Gitto, S. B., Altomare, D. A., & Copik, A. J. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1509819 · Cited by 162
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
Zamarin, D., Ricca, J. M., Sadekova, S., Oseledchyk, A., Yu, Y., Blumenschein, W. M., Wong, J., Gigoux, M., Merghoub, T., & Wolchok, J. D. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98047 · Cited by 161
Shae, D., Baljon, J. J., Wehbe, M., Christov, P. P., Becker, K. W., Kumar, A., Suryadevara, N., Carson, C. S., Palmer, C. R., Knight, F. C., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c02765 · Cited by 160
Lioux, T., Mauny, M.-A., Lamoureux, A., Nicolas, B., Hays, M., Vernejoul, F., Baudru, A.-S., Boularan, C., Lopes-Vicente, J., Qushair, G., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01300 · Cited by 129
Boasso, A., Hardy, A. W., Anderson, S. A., Dolan, M. J., & Shearer, G. M. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002961 · Cited by 128
Aptsiauri, N., Ruiz‐Cabello, F., & Garrido, F. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.006 · Cited by 125
A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells
Warashina, S., Nakamura, T., Sato, Y., Fujiwara, Y., Hyodo, M., Hatakeyama, H., & Harashima, H. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.042 · Cited by 120
Self-citationThe cGAS-STING pathway is a therapeutic target in a preclinical model of hepatocellular carcinoma
Thomsen, M. K., Skouboe, M. K., Boularan, C., Vernejoul, F., Lioux, T., Leknes, S. L., Berthelsen, M. F., Riedel, M., Cai, H., Joseph, J. V., et al. (2019) · Oncogene · doi:10.1038/s41388-019-1108-8 · Cited by 109
Liang, Y., Tang, H., Guo, J., Qiu, X., Yang, Z., Ren, Z., Sun, Z., Bian, Y., Xu, L., Xu, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06890-y · Cited by 98
Nakamura, T., Yamazaki, D., Yamauchi, J., & Harashima, H. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.004 · Cited by 92
Self-citationNakamura, T., Kuroi, M., Fujiwara, Y., Warashina, S., Sato, Y., & Harashima, H. (2016) · Scientific Reports · doi:10.1038/srep37849 · Cited by 83
Self-citationEndo, R., Nakamura, T., Kawakami, K., Sato, Y., & Harashima, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-47799-w · Cited by 72
Self-citationGarcia, Z., Lemaı̂tre, F., van Rooijen, N., Albert, M. L., Lévy, Y., Schwartz, O., & Bousso, P. (2012) · Blood · doi:10.1182/blood-2012-02-408179 · Cited by 71
Nakamura, T., Yamada, K., Fujiwara, Y., Sato, Y., & Harashima, H. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b01166 · Cited by 61
Self-citationTegtmeyer, P.-K., Spanier, J., Borst, K., Becker, J., Riedl, A., Hirche, C., Ghita, L., Skerra, J., Baumann, K., Lienenklaus, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10863-0 · Cited by 49
Kurino, T., Matsuda, R., Terui, A., Suzuki, H. Y., Kokubo, T., Uehara, T., Arano, Y., Hisaka, A., & Hatakeyama, H. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000400 · Cited by 47
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
Zamarin, D., Ricca, J. M., Sadekova, S., Oseledchyk, A., Yu, Y., Blumenschein, W. M., Wong, J., Gigoux, M., Merghoub, T., & Wolchok, J. D. (2018) · Journal of Clinical Investigation · doi:10.1172/jci125039 · Cited by 44
Application of BCG-CWS as a Systemic Adjuvant by Using Nanoparticulation Technology
Masuda, H., Nakamura, T., Noma, Y., & Harashima, H. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00919 · Cited by 38
Self-citationMasuda, H., Nakamura, T., & Harashima, H. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.02.007 · Cited by 12
Self-citation
Cited by
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Tang, Q., Chen, Y., Li, X., Long, S., Shi, Y., Yu, Y., Wu, W., Han, L., & Wang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.964442 · Cited by 561
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy
Garland, K. M., Sheehy, T. L., & Wilson, J. T. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00750 · Cited by 357
Shi, X., Wang, X., Yao, W., Shi, D., Shao, X., Lu, Z., Chai, Y., Song, J., Tang, W., & Wang, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01885-2 · Cited by 258
Metadata
- Authors
- Nakamura, T., Sato, T., Endo, R., Sasaki, S., Takahashi, N., Sato, Y., Hyodo, M., Hayakawa, Y., & Harashima, H.
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2021-07
- Volume
- 9
- Issue
- 7
- Pages
- e002852
- ISSN
- 2051-1426 (ISSN-L)
- OpenAlex
- W3177071586
- Cited by
- 257
- References
- 62
- FWCI
- 13.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.